新发 2 型糖尿病患者起始胰岛素治疗后的血糖反应和糖化血红蛋白达标情况。
Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes.
机构信息
Kaiser Permanente Center for Health Research, Portland, Oregon, USA.
出版信息
Diabetes Care. 2012 Mar;35(3):495-7. doi: 10.2337/dc11-1171. Epub 2012 Jan 25.
Abstract
OBJECTIVE
To identify the characteristics associated with glycemic response to newly initiated insulin therapy.
RESEARCH DESIGN AND METHODS
We identified 1,139 type 2 diabetic patients who initiated insulin therapy between 1 January 2009 and 30 June 2010. Outcomes of interest were the proportion of patients achieving A1C <7% and mean change in A1C within 3-9 months.
RESULTS
Mean A1C at insulin initiation was 8.2 vs. 9.2% among those who did and did not attain A1C <7% (P < 0.001). Within a mean of 5 months, 464 (40.7%) patients attained A1C <7%. In multivariable analyses controlling for insulin regimen, dose, and oral agent use, preinsulin A1C was responsible for nearly all the explained variance in A1C change. Each one percentage point of preinsulin A1C reduced the probability of attaining <7% by 26% (odds ratio 0.74 [95% CI 0.68-0.80]).
CONCLUSIONS
Insulin initiation at lower levels of A1C improves goal attainment and independently increases glycemic response.
摘要
目的
确定与新起始胰岛素治疗的血糖反应相关的特征。
研究设计和方法
我们确定了 1139 例 2009 年 1 月 1 日至 2010 年 6 月 30 日期间起始胰岛素治疗的 2 型糖尿病患者。主要观察指标为达到 A1C＜7%的患者比例和 3-9 个月内 A1C 的平均变化。
结果
起始胰岛素时 A1C 分别为 8.2%和 9.2%，<7%（P＜0.001）。在平均 5 个月内，464 例（40.7%）患者达到 A1C＜7%。在控制胰岛素方案、剂量和口服药物使用的多变量分析中，起始前 A1C 几乎可以解释 A1C 变化的所有差异。起始前 A1C 每增加 1%，达到＜7%的概率降低 26%（比值比 0.74[95%CI 0.68-0.80]）。
结论
起始胰岛素时 A1C 水平较低可提高目标达标率，独立增加血糖反应。
相似文献
1
Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes.新发 2 型糖尿病患者起始胰岛素治疗后的血糖反应和糖化血红蛋白达标情况。
Diabetes Care. 2012 Mar;35(3):495-7. doi: 10.2337/dc11-1171. Epub 2012 Jan 25.
2
Glycemic response to newly initiated diabetes therapies.新启动的糖尿病治疗的血糖反应。
Am J Manag Care. 2007 Nov;13(11):598-606.
3
Glycemic control and use of A1c in primary care patients with type 2 diabetes mellitus.2型糖尿病初级护理患者的血糖控制及糖化血红蛋白的应用
Prim Care Diabetes. 2015 Oct;9(5):385-91. doi: 10.1016/j.pcd.2015.01.006. Epub 2015 Feb 14.
4
Glycosylated hemoglobin level and number of oral antidiabetic drugs predict whether or not glycemic target is achieved in insulin-requiring type 2 diabetes.糖化血红蛋白水平和口服抗糖尿病药物的数量可预测需要胰岛素治疗的2型糖尿病患者是否能实现血糖目标。
Prim Care Diabetes. 2015 Apr;9(2):135-41. doi: 10.1016/j.pcd.2014.05.005. Epub 2014 Sep 27.
5
Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial.基础胰岛素主动滴定与常规算法滴定以及即时检测糖化血红蛋白（HbA1c）与实验室检测对2型糖尿病患者血糖控制的影响：即时检测算法与实验室糖化血红蛋白血糖优化（GOAL A1C）试验
Diabetes Care. 2006 Jan;29(1):1-8. doi: 10.2337/diacare.29.01.06.dc05-1058.
6
United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.英国前瞻性糖尿病研究24：一项为期6年的随机对照试验，比较磺脲类药物、胰岛素和二甲双胍疗法对新诊断的、饮食疗法无法控制的2型糖尿病患者的疗效。英国前瞻性糖尿病研究小组。
Ann Intern Med. 1998 Feb 1;128(3):165-75. doi: 10.7326/0003-4819-128-3-199802010-00001.
7
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.2型糖尿病患者通过饮食、磺脲类药物、二甲双胍或胰岛素进行血糖控制：对多种治疗方法的渐进性需求（英国前瞻性糖尿病研究49）。英国前瞻性糖尿病研究（UKPDS）小组
JAMA. 1999 Jun 2;281(21):2005-12. doi: 10.1001/jama.281.21.2005.
8
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.艾塞那肽与甘精胰岛素治疗2型糖尿病控制不佳患者的疗效比较：一项随机试验
Ann Intern Med. 2005 Oct 18;143(8):559-69. doi: 10.7326/0003-4819-143-8-200510180-00006.
9
Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.德国2型糖尿病患者的抗糖尿病处方与血糖控制：一项回顾性数据库研究
Clin Ther. 2007 Feb;29(2):316-25. doi: 10.1016/j.clinthera.2007.02.012.
10
Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes?AIR 胰岛素的供应是否会增加 2 型糖尿病患者的胰岛素使用量并改善血糖控制？
Diabetes Technol Ther. 2009 Sep;11 Suppl 2:S45-52. doi: 10.1089/dia.2009.0028.
引用本文的文献
1
Hypoglycemic, hypolipidemic and antioxidant effects of iridoid glycosides extracted from : possible involvement of the PI3K-Akt/PKB signaling pathway.从[具体来源]提取的环烯醚萜苷的降血糖、降血脂及抗氧化作用：PI3K-Akt/PKB信号通路可能的参与机制
RSC Adv. 2018 Aug 29;8(53):30539-30549. doi: 10.1039/c8ra06045b. eCollection 2018 Aug 24.
2
A Pragmatic Clinical Trial to Compare the Real-World Effectiveness of V-Go versus Standard Delivery of Insulin in Patients with Advanced Type 2 Diabetes.一项比较V-Go与标准胰岛素给药方式在晚期2型糖尿病患者中的真实世界有效性的实用临床试验。
J Health Econ Outcomes Res. 2019 Mar 27;6(2):70-83. doi: 10.36469/9731. eCollection 2019.
3
Clinical implications of prolonged hyperglycaemia before basal insulin initiation in type 2 diabetes patients: An electronic medical record database analysis.2型糖尿病患者起始基础胰岛素治疗前长期高血糖的临床意义：一项电子病历数据库分析
Endocrinol Diabetes Metab. 2019 Mar 28;2(3):e00061. doi: 10.1002/edm2.61. eCollection 2019 Jul.
4
Polysaccharide from Okra ( (L.) Moench) Improves Antioxidant Capacity via PI3K/AKT Pathways and Nrf2 Translocation in a Type 2 Diabetes Model.黄蜀葵多糖通过 PI3K/AKT 通路和 Nrf2 易位改善 2 型糖尿病模型的抗氧化能力。
Molecules. 2019 May 17;24(10):1906. doi: 10.3390/molecules24101906.
5
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.起始甘精胰岛素 100U/mL 治疗 2 型糖尿病患者：实现 HbA1c 目标＜7.0 的决定因素。
Diabetes Obes Metab. 2019 Feb;21(2):321-329. doi: 10.1111/dom.13607.
6
Correlations Between A1C and Diabetes Knowledge, Diabetes Numeracy, and Food Security in a Vulnerable Type 2 Diabetes Population.糖化血红蛋白（A1C）与弱势群体2型糖尿病患者的糖尿病知识、糖尿病计算能力及粮食安全之间的相关性
Diabetes Spectr. 2018 May;31(2):177-183. doi: 10.2337/ds17-0036.
7
HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups.在真实临床实践中，2 型糖尿病患者起始胰岛素治疗后的 HbA1c 反应：确定不同亚组。
Diabetes Obes Metab. 2018 Aug;20(8):1957-1964. doi: 10.1111/dom.13332. Epub 2018 May 24.
8
Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response.甘精胰岛素联合口服抗糖尿病药物治疗亚洲2型糖尿病患者：一项确定剂量和治疗反应预测因素的汇总分析
Diabetes Ther. 2018 Apr;9(2):771-787. doi: 10.1007/s13300-018-0381-9. Epub 2018 Mar 9.
9
Basal-bolus Therapy in Patients with Type 2 Diabetes Mellitus in the UK: Patient Characteristics, Treatment Patterns and the Effect of Switching to Premixed Insulin.英国2型糖尿病患者的基础-餐时胰岛素治疗：患者特征、治疗模式及转换为预混胰岛素的效果
Diabetes Ther. 2016 Dec;7(4):793-807. doi: 10.1007/s13300-016-0209-4. Epub 2016 Oct 31.
10
Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis.早期血糖反应可预测 2 型糖尿病治疗目标的后续达成情况：一项事后分析。
Diabetes Ther. 2015 Sep;6(3):317-28. doi: 10.1007/s13300-015-0119-x. Epub 2015 Jul 5.
本文引用的文献
1
Medical care costs associated with progression of diabetic nephropathy.与糖尿病肾病进展相关的医疗费用。
Diabetes Care. 2011 Nov;34(11):2374-8. doi: 10.2337/dc11-0475.
2
Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries.在 5 个欧洲国家进行的 INSTIGATE 观察性研究的 6 个月数据：在 2 型糖尿病患者中起始胰岛素治疗后的临床结局。
Curr Med Res Opin. 2011 May;27(5):887-95. doi: 10.1185/03007995.2011.555755. Epub 2011 Feb 22.
3
Standards of medical care in diabetes--2011.《糖尿病医疗护理标准——2011 年》
Diabetes Care. 2011 Jan;34 Suppl 1(Suppl 1):S11-61. doi: 10.2337/dc11-S011.
4
Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice.临床实践中二甲双胍单药治疗的初始不依从、主要失败和治疗成功。
Curr Med Res Opin. 2010 Sep;26(9):2127-35. doi: 10.1185/03007995.2010.504396.
5
Successes and challenges of insulin therapy for type 2 diabetes in a managed-care setting.在管理式医疗环境中，胰岛素治疗 2 型糖尿病的成功与挑战。
Curr Med Res Opin. 2010 Jan;26(1):9-15. doi: 10.1185/03007990903417679.
6
Glycemic response to newly initiated diabetes therapies.新启动的糖尿病治疗的血糖反应。
Am J Manag Care. 2007 Nov;13(11):598-606.
7
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.2型糖尿病患者在口服治疗基础上加用双相、餐时或基础胰岛素。
N Engl J Med. 2007 Oct 25;357(17):1716-30. doi: 10.1056/NEJMoa075392. Epub 2007 Sep 21.
8
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.2型糖尿病患者通过饮食、磺脲类药物、二甲双胍或胰岛素进行血糖控制：对多种治疗方法的渐进性需求（英国前瞻性糖尿病研究49）。英国前瞻性糖尿病研究（UKPDS）小组
JAMA. 1999 Jun 2;281(21):2005-12. doi: 10.1001/jama.281.21.2005.
Zotero 插件